...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Worst Communicating Company in History?

San Fran, 

I agree. Both companies are presenting on back to back days at BIO International on June 19 and 20. On top of that it will have been 3 months since last BETonMACE DSMB report at the end of next week, so another one may come out very soon. Furthermore, it will have been 1 year since start of ZEN-3694 dosing in the single agent trial next week. As you suggested, would be a good time to share good news on the trial results.....assuming there is good news to share. So the timing of the RVX financing seems premature. However, we all knew RVX needed the cash for ongoing and future activities, so maybe they just couldn't kick the can any longer. 

BearDownAZ 

Share
New Message
Please login to post a reply